Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 15Unknown 3Terminated 3No longer available 2Active not recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 2Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × ceritinib × Thoracic × Clear all
NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Sungkyunkwan University

Unknown
4,724 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01964157 2019-01-11

An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Yonsei University

Phase 2 Unknown
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03399487 2019-01-11

A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Yonsei University

Phase 2 Unknown
46 enrolled
Thoracic

Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Data powered by HemOnc (CC BY 4.0) Colophon âš¡